Second row: presence of a point-mutation containing aspartic acid (GAT) substituted for normal glycine (GGT). Third row : presence of a point-mutation containing cysteine (TGT) in place of normal glycine (GGT). Fifth row : presence of a point-mutation containing lysine (AAA) substituted for normal glutamic acid (CAA). Seventh row : presence of a point-mutation containing aspartic acid (GAT) substituted for normal glycine (GGT). Eighth row : presence of a pointmutation containing valin (GTT) substituted for normal glutamic acid (GGT).
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